Welcome to our dedicated page for Biorestorative Therapies SEC filings (Ticker: BRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioRestorative Therapies, Inc. (NASDAQ: BRTX) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. BioRestorative is a biotechnology issuer that develops adult stem cell-based therapies and products, and its filings offer detailed insight into the disc/spine, metabolic, and BioCosmeceutical programs that it highlights in its public communications.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which BioRestorative identifies in its S-1 registration statement as being incorporated by reference. These reports discuss risk factors, management’s discussion and analysis, and financial statements related to its clinical-stage BRTX-100 program for degenerative disc disease, the ThermoStem® metabolic platform targeting obesity and metabolic disorders, and its commercial BioCosmeceutical activities.
Investors can also examine current reports on Form 8-K that BioRestorative files to describe material events. Recent examples include disclosures about a registered direct offering of common stock with concurrent private placement of unregistered warrants, the use of proceeds for BRTX-100 clinical trials and ThermoStem® preclinical research, stockholder meeting results, and the release of quarterly financial results and corporate presentations.
In addition, this page surfaces registration statements such as Form S-1 and Form S-3, where BioRestorative outlines the terms of offerings, the status of its common stock on the NASDAQ Capital Market, and the documents incorporated by reference. Users interested in executive compensation, governance, and voting matters can consult the company’s definitive proxy statement on Schedule 14A.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as capital raises, clinical program disclosures, and stock incentive plan changes. Real-time updates from EDGAR ensure that new BRTX filings, including Forms 3, 4, and 5 related to insider transactions when available, are added promptly for ongoing analysis.
BioRestorative Therapies, Inc. filed a current report to let investors know it has made an updated corporate presentation available. The presentation may be used at conferences and investor meetings and is accessible on the company’s website as well as attached as Exhibit 99.1. The company specifies that this presentation is being furnished under a disclosure item rather than formally filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other securities filings unless specifically referenced.
Auctus Fund and affiliated reporting persons disclose beneficial ownership of 784,655 shares of BioRestorative Therapies, Inc. (BRTX), about 9.9% of the company. The disclosed position comprises 435,035 outstanding shares and 349,620 shares issuable upon exercise of warrants, and the filing is made on Schedule 13G indicating a claimed passive investment intent.
The statement notes blocker provisions that exclude 2,045,870 warrants and 1,398,158 shares issuable upon conversion from the reported beneficial ownership; without those blockers the aggregate exposure could be 4,228,683 shares. The reporting persons state shared voting and dispositive power over the 784,655 shares.
BioRestorative Therapies, Inc. reported a net loss of $7,996,062 for the six months ended June 30, 2025 and a net loss of $2,656,263 for the quarter. Revenue for the three months ended June 30, 2025 was $303,300 versus $89,100 in the prior-year quarter, driven by $300,000 of cosmetic product sales and smaller royalty receipts. Cash and cash equivalents were $1,555,251 and investments in marketable securities were $5,825,685, resulting in working capital of $3,926,572.
The company disclosed substantial doubt about its ability to continue as a going concern, citing ongoing net losses and negative operating cash flow of $5,472,653 for the six months. R&D expense rose to $4,872,782 for six months largely due to Phase 2 clinical trial costs. Management raised net proceeds of $1,938,445 from ATM sales during the period, recorded $2,580,379 of warrant liabilities, and reported material weaknesses in internal control over financial reporting.
BioRestorative Therapies, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The release also provided a business update and included details for a conference call to discuss the quarter. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The filing states that the information furnished is summary information to be considered in the context of the Company’s SEC filings and other public announcements. The Company expressly furnishes the press release (it is not being filed for purposes of Section 18 of the Exchange Act) and does not incorporate the press release by reference into other registration statements unless specifically stated.
BioRestorative Therapies, Inc. is soliciting proxies for its 2025 Annual Meeting to be held September 18, 2025, where stockholders will vote on two Class II director nominees, an amendment to increase the 2021 Stock Incentive Plan authorized shares from 6,850,000 to 9,850,000, ratification of CBIZ CPAs P.C. as the independent auditor for fiscal 2025, and a non-binding advisory vote on executive compensation. Only stockholders of record as of July 31, 2025 may vote; there were 7,978,117 common shares and 1,398,158 Series B preferred shares outstanding on that date.
Executive pay highlights: CEO Lance Alstodt’s 2024 total reported compensation was $1,314,583 (compensation actually paid $1,202,070). Pay-versus-performance figures show cumulative TSR on a $100 investment of $32.95 (2024) with net losses of $(8,979,381) in 2024, $(10,417,704) in 2023 and $(13,222,296) in 2022. The proxy discloses identified material weaknesses in internal control over financial reporting and the auditor transition from Marcum LLP to CBIZ CPAs following Marcum’s attest business acquisition.